MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 نوفمبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 أكتوبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

28 سبتمبر 2023 22:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

28 سبتمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 سبتمبر 2023 16:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

13 سبتمبر 2023 09:10:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

11 سبتمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

08 أغسطس 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

17 يوليو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

30 يونيو 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

22 يونيو 2023 03:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Supports International NASH Day on June 8

06 يونيو 2023 08:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

01 يونيو 2023 08:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

11 مايو 2023 08:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

09 مايو 2023 08:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial

18 أبريل 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

23 فبراير 2023 08:00:02 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

08 فبراير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

06 يناير 2023 08:00:00 بحسب Nasdaq GlobeNewswire